Our findings of DNA damage induced by DNA damage repair blockage promoting recruitment of anti-tumor immune cells provide the preclinical evidence for the combination of CHK1 blockade and ICI use in HCC. This evidence concerns the gene CHEK1 and hepatocellular carcinoma.